Heart failure is a leading cause of mortality worldwide. Specified diagnostic approach for heart failure remains a serious dilemma for scientist and physicians. It’s the need of time to develop the cost effective specified diagnostic strategies that may predict the heart damage at pre and post ischemic stage. Therefore, the current study aimed to develop assay based on Endothelin-1 as the diagnostic marker for periodic heart failure. Endothelin-1 is a potent neuro-hormone is involved in the vasoconstriction after binding to respective G-coupled receptor and mediated cardiac signaling. In preliminary studies, we have worked on elucidating the role of Endothelin-1 in different experimental models of cardiac disorders. Diabetes induced cardiac hypertrophy model and cardiac ischemia models were established and confirmed by assessing morphological parameters, heart weight/body weight, heart weight/tibia length, cell surface area, histopathological examination and molecular cardiac biomarkers. Lipid peroxidation, oxidative and antioxidative profile analysis were also performed to delineate the pathways involved in cardiovascular signaling. The expression of endothelin- 1 was assessed in invitro and invivo models both at transcriptional and translational level. This diagnostic model may serve as potential molecular indicator of heart health.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Metabolism - Clinical and Experimental
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect